Komipharm International Co. Ltd Net Assets
Komipharm International Co. Ltd net assets. Based on the latest financial reports, Komipharm International Co. Ltd (041960) has net assets worth ₩72.06 Billion KRW (≈ $48.83 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩133.92 Billion ≈ $90.75 Million USD) and total liabilities (₩61.86 Billion ≈ $41.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Komipharm International Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩72.06 Billion |
| % of Total Assets | 53.81% |
| Annual Growth Rate | 4.44% |
| 5-Year Change | 8.42% |
| 10-Year Change | -22.69% |
| Growth Volatility | 15.7 |
Net Assets of Komipharm International Co. Ltd (2011–2025)
Net assets of Komipharm International Co. Ltd from 2011 to 2025. This chart illustrates how Komipharm International Co. Ltd's net assets have evolved over time, based on quarterly financial data. See 041960 equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Komipharm International Co. Ltd (2011–2025)
The table below shows the annual net assets of Komipharm International Co. Ltd from 2011 to 2025. For live market cap and overall valuation, see 041960 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩72.06 Billion ≈ $48.83 Million |
+9.95% |
| 2024-12-31 | ₩65.54 Billion ≈ $44.41 Million |
+9.20% |
| 2023-12-31 | ₩60.02 Billion ≈ $40.67 Million |
-1.02% |
| 2022-12-31 | ₩60.63 Billion ≈ $41.09 Million |
-8.77% |
| 2021-12-31 | ₩66.46 Billion ≈ $45.04 Million |
-12.87% |
| 2020-12-31 | ₩76.28 Billion ≈ $51.69 Million |
+4.09% |
| 2019-12-31 | ₩73.28 Billion ≈ $49.66 Million |
-21.54% |
| 2018-12-31 | ₩93.39 Billion ≈ $63.29 Million |
-7.78% |
| 2017-12-31 | ₩101.27 Billion ≈ $68.63 Million |
+8.65% |
| 2016-12-31 | ₩93.20 Billion ≈ $63.16 Million |
+22.43% |
| 2015-12-31 | ₩76.13 Billion ≈ $51.59 Million |
+43.21% |
| 2014-12-31 | ₩53.16 Billion ≈ $36.02 Million |
+18.87% |
| 2013-12-31 | ₩44.72 Billion ≈ $30.31 Million |
+10.24% |
| 2012-12-31 | ₩40.56 Billion ≈ $27.49 Million |
+3.38% |
| 2011-12-31 | ₩39.24 Billion ≈ $26.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Komipharm International Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4249.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Komipharm International Co. Ltd Net Assets Breakdown (December 2025)
Komipharm International Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩87.42 Billion | 125.71% |
| Total Equity | ₩69.54 Billion | 100.00% |
Komipharm International Co. Ltd Competitors by Market Cap
The table below lists competitors of Komipharm International Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tidewater Midstream and Infrastructure Ltd
TO:TWM
|
$349.94 Million |
|
Jw Pharmac
KO:001060
|
$349.95 Million |
|
Zhenhai PetroChem Engineering
SHG:603637
|
$349.97 Million |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
$350.09 Million |
|
Roma Green Finance Limited Ordinary Shares
NASDAQ:ROMA
|
$349.85 Million |
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
$349.84 Million |
|
Atria Oyj A
HE:ATRAV
|
$349.74 Million |
|
Glarner Kantonalbank
SW:GLKBN
|
$349.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Komipharm International Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 62,280,266,440 to 69,538,619,610, a change of 7,258,353,170 (11.7%).
- Net loss of 7,208,746,050 reduced equity.
- Share repurchases of 2,878,833,730 reduced equity.
- Other factors increased equity by 17,345,932,950.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.21 Billion | -10.37% |
| Share Repurchases | ₩2.88 Billion | -4.14% |
| Other Changes | ₩17.35 Billion | +24.94% |
| Total Change | ₩- | 11.65% |
Book Value vs Market Value Analysis
This analysis compares Komipharm International Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.02x to 9.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1482.79 | ₩8930.00 | x |
| 2017-12-31 | ₩1599.65 | ₩8930.00 | x |
| 2018-12-31 | ₩1468.76 | ₩8930.00 | x |
| 2019-12-31 | ₩1151.66 | ₩8930.00 | x |
| 2020-12-31 | ₩1193.90 | ₩8930.00 | x |
| 2021-12-31 | ₩945.11 | ₩8930.00 | x |
| 2022-12-31 | ₩864.12 | ₩8930.00 | x |
| 2023-12-31 | ₩803.07 | ₩8930.00 | x |
| 2024-12-31 | ₩898.99 | ₩8930.00 | x |
| 2025-12-31 | ₩969.83 | ₩8930.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Komipharm International Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.74%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.93x
- Recent ROE (-10.37%) is below the historical average (-5.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 2.49% | 4.57% | 0.29x | 1.90x | ₩-3.05 Billion |
| 2014 | -4.04% | -6.24% | 0.28x | 2.34x | ₩-7.47 Billion |
| 2015 | -8.60% | -17.99% | 0.27x | 1.75x | ₩-14.16 Billion |
| 2016 | 0.31% | 0.77% | 0.25x | 1.61x | ₩-9.03 Billion |
| 2017 | -5.03% | -13.91% | 0.25x | 1.47x | ₩-15.22 Billion |
| 2018 | -15.32% | -40.87% | 0.25x | 1.50x | ₩-23.64 Billion |
| 2019 | -29.15% | -60.20% | 0.28x | 1.71x | ₩-28.69 Billion |
| 2020 | -3.69% | -7.58% | 0.30x | 1.60x | ₩-10.44 Billion |
| 2021 | -6.71% | -12.44% | 0.31x | 1.73x | ₩-11.11 Billion |
| 2022 | -10.74% | -16.37% | 0.36x | 1.84x | ₩-12.58 Billion |
| 2023 | -7.06% | -9.33% | 0.36x | 2.11x | ₩-9.61 Billion |
| 2024 | 21.06% | 22.31% | 0.48x | 1.97x | ₩6.89 Billion |
| 2025 | -10.37% | -13.74% | 0.39x | 1.93x | ₩-14.16 Billion |
Industry Comparison
This section compares Komipharm International Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $93,036,273,124
- Average return on equity (ROE) among peers: 4.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Komipharm International Co. Ltd (041960) | ₩72.06 Billion | 2.49% | 0.86x | $349.86 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $2.67 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $110.44 Billion | 10.69% | 0.73x | $21.02 Million |
| NatureCell Co.Ltd (007390) | $64.62 Billion | 1.90% | 0.11x | $793.12 Million |
| Sam-A Pharm. Co. Ltd (009300) | $79.92 Billion | 4.39% | 0.39x | $55.96 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $228.87 Billion | 3.73% | 0.41x | $78.73 Million |
| WooGene B&G Co. Ltd (018620) | $18.56 Billion | 6.88% | 0.41x | $47.95 Million |
| Oscotec Inc (039200) | $53.05 Billion | -8.21% | 0.44x | $674.16 Million |
| EstechPharma Co. Ltd (041910) | $115.63 Billion | 3.31% | 0.05x | $43.06 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $51.91 Billion | 7.60% | 0.23x | $25.14 Million |
About Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more